Aromatase inhibitors (AIs; e.g., letrozole, anastrozole, and exemestane), selective estrogen receptor modulators (e.g., fulvestrant), and selective estrogen receptor modulators (e.g., tamoxifen) have essential roles in the treatment of HR+/HER2− breast cancer. Here, ESR1 is linked to breast cancer.